Gelonghui November 27丨Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that patients often showed upper respiratory symptoms after syncytial virus infection. Injecting thymopeptide in the company's products can prevent upper respiratory infections. Junyuan Pharmaceutical and Cyerbio, a holding subsidiary of the company, have products suitable for upper respiratory infections, and drug use must be in accordance with medical advice.
赛升药业(300485.SZ)：产品注射用胸腺肽可预防上呼吸道感染
Saisheng Pharmaceutical (300485.SZ): Injecting thymotide products can prevent upper respiratory infections
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.